Logo image of IMCC

IM CANNABIS CORP (IMCC) Stock Fundamental Analysis

NASDAQ:IMCC - Nasdaq - CA44969Q4060 - Common Stock - Currency: USD

2.91  -0.53 (-15.41%)

After market: 2.99 +0.08 (+2.75%)

Fundamental Rating

3

Overall IMCC gets a fundamental rating of 3 out of 10. We evaluated IMCC against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IMCC have multiple concerns. IMCC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

IMCC had negative earnings in the past year.
In the past year IMCC had a positive cash flow from operations.
In the past 5 years IMCC always reported negative net income.
In the past 5 years IMCC always reported negative operating cash flow.
IMCC Yearly Net Income VS EBIT VS OCF VS FCFIMCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -10.43%, IMCC is in the better half of the industry, outperforming 68.56% of the companies in the same industry.
IMCC has a Return On Equity of -88.04%. This is comparable to the rest of the industry: IMCC outperforms 42.78% of its industry peers.
Industry RankSector Rank
ROA -10.43%
ROE -88.04%
ROIC N/A
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
IMCC Yearly ROA, ROE, ROICIMCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

With a Gross Margin value of 18.58%, IMCC perfoms like the industry average, outperforming 52.06% of the companies in the same industry.
IMCC's Gross Margin has improved in the last couple of years.
IMCC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
IMCC Yearly Profit, Operating, Gross MarginsIMCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

IMCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMCC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IMCC has been increased compared to 5 years ago.
IMCC has a worse debt/assets ratio than last year.
IMCC Yearly Shares OutstandingIMCC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
IMCC Yearly Total Debt VS Total AssetsIMCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

IMCC has an Altman-Z score of -7.25. This is a bad value and indicates that IMCC is not financially healthy and even has some risk of bankruptcy.
IMCC has a Altman-Z score of -7.25. This is in the lower half of the industry: IMCC underperforms 65.98% of its industry peers.
The Debt to FCF ratio of IMCC is 4.09, which is a neutral value as it means it would take IMCC, 4.09 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of IMCC (4.09) is better than 86.60% of its industry peers.
A Debt/Equity ratio of 2.52 is on the high side and indicates that IMCC has dependencies on debt financing.
IMCC has a Debt to Equity ratio of 2.52. This is in the lower half of the industry: IMCC underperforms 78.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF 4.09
Altman-Z -7.25
ROIC/WACCN/A
WACC11.68%
IMCC Yearly LT Debt VS Equity VS FCFIMCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

IMCC has a Current Ratio of 0.72. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
IMCC has a worse Current ratio (0.72) than 89.69% of its industry peers.
A Quick Ratio of 0.59 indicates that IMCC may have some problems paying its short term obligations.
IMCC has a Quick ratio of 0.59. This is amonst the worse of the industry: IMCC underperforms 88.14% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.59
IMCC Yearly Current Assets VS Current LiabilitesIMCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

IMCC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -78.84%.
IMCC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.68%.
IMCC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.64% yearly.
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.54%
Revenue 1Y (TTM)12.68%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%3.62%

3.2 Future

The Earnings Per Share is expected to grow by 36.54% on average over the next years. This is a very strong growth
IMCC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.24% yearly.
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IMCC Yearly Revenue VS EstimatesIMCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
IMCC Yearly EPS VS EstimatesIMCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

IMCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMCC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMCC Price Earnings VS Forward Price EarningsIMCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

IMCC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IMCC is cheaper than 99.48% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.19
EV/EBITDA N/A
IMCC Per share dataIMCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

IMCC's earnings are expected to grow with 36.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMCC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IM CANNABIS CORP

NASDAQ:IMCC (7/11/2025, 8:24:18 PM)

After market: 2.99 +0.08 (+2.75%)

2.91

-0.53 (-15.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2025-05-15
Earnings (Next)08-12 2025-08-12
Inst Owners3.87%
Inst Owner Change0%
Ins Owners53.08%
Ins Owner ChangeN/A
Market Cap8.99M
Analysts82.86
Price TargetN/A
Short Float %0.54%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.69%
Min Revenue beat(2)-25.65%
Max Revenue beat(2)-9.73%
Revenue beat(4)1
Avg Revenue beat(4)-9.56%
Min Revenue beat(4)-25.65%
Max Revenue beat(4)9.9%
Revenue beat(8)3
Avg Revenue beat(8)-4.84%
Revenue beat(12)3
Avg Revenue beat(12)-9.88%
Revenue beat(16)5
Avg Revenue beat(16)-5.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.23
P/FCF 3.19
P/OCF 3.07
P/B 2.31
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.47
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)0.91
FCFY31.34%
OCF(TTM)0.95
OCFY32.59%
SpS12.87
BVpS1.26
TBVpS-1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.43%
ROE -88.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.58%
FCFM 7.09%
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
F-Score7
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF 4.09
Debt/EBITDA N/A
Cap/Depr 7.98%
Cap/Sales 0.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.72
Quick Ratio 0.59
Altman-Z -7.25
F-Score7
WACC11.68%
ROIC/WACCN/A
Cap/Depr(3y)15.95%
Cap/Depr(5y)83.89%
Cap/Sales(3y)1.45%
Cap/Sales(5y)6.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.54%
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.68%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%3.62%
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y66.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.87%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y136.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.37%
OCF growth 3YN/A
OCF growth 5YN/A